Boehringer-Ingelheim Now RE-LYing On Pradaxa Approval In Stroke Prevention

As Boehringer-Ingelheim scrambles to file its oral anticoagulant Pradaxa with FDA, likely for stroke prevention in patients with atrial fibrillation, physicians already have started weighing the pros and cons of the drug's two possible doses